AI assistant
Sending…
Vaxcyte, Inc. — Director's Dealing 2024
Feb 20, 2024
31100_dirs_2024-02-20_35237cda-848e-4bc8-9dc4-73cc36e4b0d0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2024-02-15
Reporting Person: Wassil Jim (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-02-15 | Common Stock | M | 27917 | $2.42 | Acquired | 203852 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-02-15 | Stock Option (right to buy) | $2.42 | M | 27917 | Disposed | 2029-12-16 | Common Stock (27917) | Direct |
Footnotes
F1: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter.
More from Vaxcyte, Inc.
Regulatory Filings
2026
May 6
Proxy Solicitation & Information Statement
2026
Apr 23
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 19
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Regulatory Filings
2026
Feb 24